Description

Semaglutide 2.4 mg weekly led to significant resolution of MASH and reduction in fibrosis after 72 weeks 🌟🧬.

Patients lost more weight ⚖️, showed better liver markers 📉, and had improved metabolic profiles 💉.

GI side effects were common 🤢, but no new safety signals emerged ✅.

Promising dual-action therapy for liver and cardiometabolic health! ❤️🩺